Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Required: EGFR testing required if tissue available (testing required; no eligibility threshold specified)

Provide tumor tissue, whenever possible, for EGFR testing

Required: HPV testing required for oropharyngeal cancer if tissue available (testing required; no eligibility threshold specified)

for oropharyngeal cancer, provide tissue for HPV/p16 testing if feasible

Cannot have received: pd-1 inhibitor

Exception: within 4 weeks prior to enrollment

Cannot have received: egfr monoclonal antibody

Exception: within 4 weeks prior to enrollment

Cannot have received: egfr tyrosine kinase inhibitor

Exception: within 4 weeks prior to enrollment

Cannot have received: anti-angiogenic agent

Exception: within 4 weeks prior to enrollment